Adagene Expands Collaboration with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Adagene Inc. has amended its 2021 collaboration agreement with Exelixis, allowing Exelixis to use Adagene’s SAFEbody technology to develop a masked monoclonal antibody for an antibody-drug conjugate targeting solid tumors. Adagene will benefit from development milestones and royalties on net sales from this collaboration, highlighting the potential of its SAFEbody technology in improving cancer therapies.
Adagene Inc. has announced an amendment to its 2021 collaboration and license agreement with Exelixis. The revised deal will see Exelixis utilizing Adagene’s SAFEbody technology platform to develop a masked monoclonal antibody from Adagene’s pipeline. This will be used to create an antibody-drug conjugate targeting a solid tumor as identified by Exelixis. Adagene stands to gain from development and commercialization milestones, as well as receive royalties on the net sales of products developed from this collaboration. The partnership underscores the potential of Adagene’s SAFEbody technology in enhancing the safety and efficacy of targeted cancer therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9529630-en) on September 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
